Novonesis consensus picture on Tuesday, shares tracked against biotech peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 22:01.

Novonesis (DK0060336014) is listed on Nasdaq Copenhagen and targets the biotech and biosolutions segment in Europe. On this Tuesday, investors focus on the consensus landscape and how the shares compare to sector names such as Novo Nordisk and Chr. Hansen, according to data providers that compile forecasts for the Danish market.

What analyst data show

For Novonesis, several banks and brokers publish earnings and rating data, with the stock typically covered in the European chemicals and biotechnology context on platforms such as MarketScreener and finanzen.net, which aggregate analyst inputs for Danish names including Novonesis and Novo Nordisk.MarketScreener overview for Danish large caps The consensus picture for comparable Nordic healthcare and biotech stocks still shows a predominance of positive recommendations, as illustrated by Morningstar’s recent coverage of Novo Nordisk where the house maintains a target of 343 Danish kroner while moving the rating to Hold for that peer.Morningstar note on Novo Nordisk

Within the European biotech universe, Novonesis is often grouped with specialty enzyme producers and biosolutions providers, and valuations are watched against larger pharma and biotech constituents of the OMX Copenhagen 25 and Stoxx Europe 600 indices, where peers such as Novo Nordisk and Novartis operate with higher market capitalizations and broader product portfolios.Coverage of Novo Nordisk in European indices

How the shares are quoted

Quote platforms such as finanzen100 show Novonesis B with the ISIN DK0060336014, WKN A1JP9Y and the symbol NZM2, and on Tuesday the shares change hands around 55 euros in German trading, highlighting interest beyond the home Nasdaq Copenhagen listing.finanzen100 data for Novonesis B The stock is classified to the chemicals sector with a biotechnology tilt, which places it next to European specialty chemicals and life sciences names in sector overviews.

For comparison, Novo Nordisk B shares most recently traded around 315 Danish kroner on Nasdaq Copenhagen, with Reuters noting that the group’s US executive is lobbying for broader insurance coverage of the obesity drug Wegovy, underlining how regulatory and reimbursement themes can influence Nordic healthcare valuations.Reuters report on Novo Nordisk US unit

The biosolutions business model

Novonesis, formed around the former Novozymes franchise, generates revenue with industrial enzymes and microbial solutions used in detergents, food and beverage, agriculture and bioenergy applications, according to its investor communications and product descriptions.Company information on Novonesis The group markets specific enzyme products to global consumer goods and industrial clients, positioning itself as a provider of efficiency and sustainability gains in production processes.

Where the shares trade today

The Novonesis shares (DK0060336014) trade on 2026-06-25, 21:54 on the Lang & Schwarz platform at 55.20 euros, based on indicative pricing quoted by finanzen100 for the NZM2 line that mirrors the Nasdaq Copenhagen listing.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Figures and assessments are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions.